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Cannabis sativa L. is an annual herbaceous plant in the Cannabis genus, a species of the Cannabaceae family. People have 
cultivated Cannabis sativa throughout recorded history as a source of industrial fibre, seed oil, food, recreation, religious 
and spiritual moods, and medicine. Each part of the plant is harvested differently, depending on the purpose of its use. 
 
 
                     
        
                                                   Figure 1. The images of the leaves of Cannabis sativa L 
 
Broadly, there are three main cultivar groups of cannabis that are cultivated today: Cultivars primarily cultivated for their 
fibre, characterised by long stems and little branching, cultivars grown for seed which can be eaten entirely raw or from 
which hemp oil is extracted and cultivars grown for medicinal or recreational purposes. A nominal if not legal distinction is 
often made between industrial hemp, with concentrations of psychoactive compounds far too low to be useful for that 
purpose, and marijuana. 
Cannabis chemical constituents include about 100 compounds responsible for its psychoactive characteristics, as well, as 
aroma. These are mainly volatile terpenes and sesquiterpenes. Although the main psychoactive constituent of Cannabis is 
tetrahydrocannabinol (THC), the plant is known to contain about sixty cannabinoids; however, most of these "minor" 
cannabinoids are only produced in trace amounts. 
                                             
Figure 2.  Chemical structure of Δ9-tetrahydrocannabinol (THC)                Figure 3.  Chemical structure of cannabidiol 
 
Besides THC, another cannabinoid produced in high concentrations by some plants is cannabidiol (CBD), which is not 
psychoactive but has recently been shown to block the effect of THC in the nervous system. CBD is a major 
phytocannabinoid, accounting for up to 40% of the plant's extract. CBD is considered to have a wider scope of medical 
applications than tetrahydrocannabinol (THC). An orally-administered liquid containing CBD has received orphan drug 
status in the US, for use as a treatment for Dravet syndrome. 
The mainly volatile terpenes and sesquiterpenes which are responsible for specific aroma of the plant are: Myrcene, linalool, 
limonene, trans-β-ocimene, α-terpinolene, trans-caryophyllene, α-humulene, caryophyllene oxide (some hashish detection 
dogs are trained to detect the smell of caryophyllene oxide) etc.  
 
Marijuana is a preparation of the Cannabis sativa L. plant intended for use as a psychoactive drug and as medicine. Marijuana is the mixture 
made of flowers (female hemp plant in flower), leaves and small stems of Cannabis sativa. Pharmacologically, the principal psychoactive 
constituent of cannabis is THC (6%).  
 
 
 
 
 
Figure 4. The image of marijuana ready for consumption 
 
 
Throughout human history marijuana has been used for many purposes such as recreation, therapy, art, religion, medicine as 
a textile. The origin of marijuana dates from six thousands years ago when many different tribes used it for different 
celebrations and rituals. There are documents that show that marijuana was used even in the time of Chinese Emperor Shen 
Nung in 2337 BC. They used it in their funeral rituals. Seeds of this plant were found in their funeral urns. This plant was 
also used for treating insomnia, healing and also as painkiller. Each culture and subculture from prehistory up to now use 
this plant because it causes selective changes in consciousness of its consumers strictly dosing what is beyond reality, and 
also for medical reasons. Medicinal use of marijuana arrived in Europe from the East during the 18th century. It was 
brought to Europe much later, but it was not less popular. It reaches the high society very soon. In Paris, a club was open 
where many famous people, even Balzac, enjoyed marijuana. 
 
 
                                                                           
 
 
Figure 5. "Dàmá", the Chinese word for "cannabis"                              Figure 6. The Ebers Papyrus (ca. 1550 BCE) from Ancient Egypt  
 has a prescription for medical marijuana applied directly for inflammation. 
 
 
Figure 7 Cannabis sativa scientific drawings from 19
th
 century 
 
 
 The first comprehensive description of the medical use of Indian hemp in Europe was written in 1830 by the German 
pharmacist Friedrich Ludwig Nees von Esenbeck. Until that point in time, use of marijuana for medical purposes had 
remained at a low level. Thanks mainly to the work of W.B.O’Shaugnessy in 1839 marijuana become recognized within 
European – school medicine. He used various hemp compounds in his investigations, partly with great success, against 
rheumatism, rabies, cholera, tetanus, convulsions and delirium tremens. The prestigious US Institute of Medicine published 
its report Medical Use of Marijuana in 1999. Recent studies reviewed by Park et al. 2004 that marijuana, THC and other 
exogenous cannabinoids exert potent effects on the endocannabinoid system in both the gonads and during pregnancy. 
These reports established the evidence base to support the further examination of cannabis products for medical use.  
Today marijuana is forbidden in many countries for its narcotic and negative influence to the nerve system. In some cultures 
marijuana was a protected mark, other cultures were its big admirers and third do not know or do not look on that way about 
marijuana. The use of marijuana was legalized in the Netherlands in 2003 and extended for a five – year period in 2007. 
 
 
 
 Some investigations which have been conducted in several European countries within recent ten years revealed easy 
availability of the drug on the illicit market. According to these studies availability of cannabis can be indirectly inferred on 
the data of perceived availability, police seizures data and also prices of the drug on the street as they indicate economic 
accessibility of drug as related to incomes. A few conclusions can be drawn from Figure 8. First cannabis seems to be fairly 
easy available for a substantial proportion of students in all countries under review form. 
 
 
   
 
Figure 8. Availability of the drug on illicit market 
 
Conclusion 
 
 
The usage of marijuana through the ages has been accompanied by a lot of controversies. Measuring the proportion of 
problematic or dependent cannabis users from among the wider cannabis user base is complex. It presents far more 
challenges than measuring prevalence by lifetime or last month cannabis use in general population surveys. Faced with an 
increase in cannabis use, policymakers may choose to add some tools to general population surveys or the monitoring 
instruments used by addiction treatment centres.  
Today, a great number of concepts and tools exist to monitor problematic cannabis use, and they vary in terms of both 
quality and robust scientific validation. Nonetheless, these instruments do offer valuable insights into use patterns. 
Implementing a common screening tool, even if not validated, can deliver important information to inform the fields of 
prevention and treatment. Policymakers should be prepared for some criticism based on the lack of consensus surrounding 
dependence and abuse, but screening at least delivers a base of knowledge that can be used by specialists in defining public 
policy. 
There is clearly a need to develop screening tools that are more reliable in measuring adverse effects of cannabis use than 
those presently in use. Some existing instruments, such as CIDI and CAST, go some way to providing a standard, practical 
tool, and can provide a basis for further work. In Europe, screening projects for cannabis are under way in Germany, France, 
the Netherlands, Poland, Portugal, the United Kingdom and, most recently, Spain (EMCDDA, 2007). It is hoped that such 
initiatives will help to develop a reliable and comparable indicator of problematic cannabis use in the general population. 
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